Skip to content

Author

Filippo Rocca

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Long-term safety and efficacy of efgartigimod in generalized myasthenia gravis during the ADAPT+ study

Background: Efgartigimod is a human immunoglobulin G1 (IgG1) antibody Fc-fragment that reduces total and pathogenic IgG autoantibody levels through neonatal Fc receptor blockade. ADAPT was a 26-week, global, multicenter, randomized, placebo-controlled, phase 3 trial evaluating efgartigimod in participants with generali...

Filippo Rocca, James F. Howard, M. Pasnoor et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.